
Isabelle Huys

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4664284/publications.pdf Version: 2024-02-01



ISARFILE HUVS

#	Article	lF	CITATIONS
1	Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. BioDrugs, 2022, 36, 217-229.	2.2	15
2	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Frontiers in Medicine, 2022, 9, 820755.	1.2	16
3	Digitizing the Informed Consent Process: A Review of the Regulatory Landscape in the European Union. Frontiers in Medicine, 2022, 9, .	1.2	7
4	Co-creation with research participants to inform the design of electronic informed consent. Digital Health, 2022, 8, 205520762211090.	0.9	3
5	Biosimilars in Belgium: a proposal for a more competitive market. Acta Clinica Belgica, 2021, 76, 441-452.	0.5	13
6	Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer. Clinical and Translational Science, 2021, 14, 47-53.	1.5	4
7	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. Haemophilia, 2021, 27, 129-136.	1.0	27
8	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discovery Today, 2021, 26, 399-415.	3.2	20
9	A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. BioDrugs, 2021, 35, 75-87.	2.2	11
10	Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives. Patient, 2021, 14, 119-128.	1.1	23
11	Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study. Patient, 2021, 14, 601-612.	1.1	8
12	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals, 2021, 14, 117.	1.7	30
13	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. Frontiers in Medicine, 2021, 8, 595797.	1.2	8
14	A comprehensive review on non-clinical methods to study transfer of medication into breast milk – A contribution from the ConcePTION project. Biomedicine and Pharmacotherapy, 2021, 136, 111038.	2.5	19
15	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Frontiers in Pharmacology, 2021, 12, 644187.	1.6	14
16	Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices. Pharmaceuticals, 2021, 14, 499.	1.7	18
17	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. Journal of Pharmaceutical Policy and Practice, 2021, 14, 53.	1.1	7
18	Personalized and long-term electronic informed consent in clinical research: stakeholder views. BMC Medical Ethics, 2021, 22, 108.	1.0	15

ISABELLE HUYS

#	Article	IF	CITATIONS
19	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. Haemophilia, 2021, 27, 957-966.	1.0	14
20	Clinical Research in Neonates: Redesigning the Informed Consent Process in the Digital Era. Frontiers in Pediatrics, 2021, 9, 724431.	0.9	2
21	Strengthening the global network for sharing of marine biological collections: recommendations for a new agreement for biodiversity beyond national jurisdiction. ICES Journal of Marine Science, 2021, 78, 305-314.	1.2	12
22	Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. Exploratory Research in Clinical and Social Pharmacy, 2021, 4, 100084.	0.6	2
23	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology, 2021, 12, 789640.	1.6	6
24	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. BioDrugs, 2020, 34, 159-170.	2.2	75
25	Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and Reality. Frontiers in Medicine, 2020, 7, 585722.	1.2	5
26	Practical Implications From European Hospital Pharmacists on Prospective Risk Assessment for Medicine Shortages. Frontiers in Medicine, 2020, 7, 407.	1.2	6
27	An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?. Health Policy, 2020, 124, 1325-1332.	1.4	28
28	European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice. BioDrugs, 2020, 34, 797-808.	2.2	33
29	European Stakeholder Learnings Regarding Biosimilars: Part l—Improving Biosimilar Understanding and Adoption. BioDrugs, 2020, 34, 783-796.	2.2	39
30	Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals, 2020, 13, 324.	1.7	20
31	Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. Frontiers in Pharmacology, 2020, 11, 594446.	1.6	21
32	Risks in Antibiotic Substitution Following Medicine Shortage: A Health-Care Failure Mode and Effect Analysis of Six European Hospitals. Frontiers in Medicine, 2020, 7, 157.	1.2	20
33	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clinical Pharmacology and Therapeutics, 2020, 108, 734-755.	2.3	86
34	Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective. Frontiers in Medicine, 2020, 7, 33.	1.2	8
35	Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making. Frontiers in Pharmacology, 2020, 11, 43.	1.6	14
36	Patient Centricity in Patient Preference Studies: The Patient Perspective. Frontiers in Medicine, 2020, 7, 93.	1.2	14

ISABELLE HUYS

#	Article	lF	CITATIONS
37	An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. MAbs, 2020, 12, 1743517.	2.6	31
38	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. Frontiers in Pharmacology, 2020, 11, 591134.	1.6	44
39	Conducting Non-COVID-19 Clinical Trials during the Pandemic: Can Today's Learning Impact Framework Efficiency?. European Journal of Health Law, 2020, 27, 425-450.	0.1	8
40	Improving Patient Preference Elicitation by Applying Concepts From the Consumer Research Field: Narrative Literature Review. Interactive Journal of Medical Research, 2020, 9, e13684.	0.6	2
41	Implementation of Electronic Informed Consent in Biomedical Research and Stakeholders' Perspectives: Systematic Review. Journal of Medical Internet Research, 2020, 22, e19129.	2.1	43
42	A study protocol for quantifying patient preferences in neuromuscular disorders: a case study of the IMI PREFER Project. Wellcome Open Research, 2020, 5, 253.	0.9	4
43	What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population. Applied Health Economics and Health Policy, 2019, 17, 895-902.	1.0	3
44	Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet Journal of Rare Diseases, 2019, 14, 99.	1.2	65
45	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today, 2019, 24, 1324-1331.	3.2	90
46	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting. BioDrugs, 2019, 33, 299-306.	2.2	16
47	Protection of Phage Applications in Crop Production: A Patent Landscape. Viruses, 2019, 11, 277.	1.5	15
48	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting. BioDrugs, 2019, 33, 285-297.	2.2	23
49	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. Frontiers in Pharmacology, 2019, 10, 1395.	1.6	48
50	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. Drug Discovery Today, 2019, 24, 57-68.	3.2	69
51	Noninvasive prenatal testing: a survey of young (future) parents in Flanders. Personalized Medicine, 2018, 15, 35-43.	0.8	4
52	The necessity for a European definition of drug shortages. International Journal of Pharmacy Practice, 2018, 26, 289-290.	0.3	3
53	Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. BioDrugs, 2017, 31, 447-459.	2.2	65
54	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Frontiers in Pharmacology, 2017, 8, 314.	1.6	80

ISABELLE HUYS

#	ARTICLE	IF	CITATIONS
55	Innovative Approaches to Increase Access to Medicines in Developing Countries. Frontiers in Medicine, 2017, 4, 218.	1.2	41
56	Policies for biosimilar uptake in Europe: An overview. PLoS ONE, 2017, 12, e0190147.	1.1	153
57	Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs. Frontiers in Pharmacology, 2016, 7, 144.	1.6	7
58	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. Frontiers in Pharmacology, 2016, 7, 193.	1.6	65
59	Intellectual property policies in early-phase research in public–private partnerships. Nature Biotechnology, 2016, 34, 504-510.	9.4	14
60	Qualitative study on custodianship of human biological material and data stored in biobanks. BMC Medical Ethics, 2016, 17, 15.	1.0	12
61	Toward a European definition for a drug shortage: a qualitative study. Frontiers in Pharmacology, 2015, 6, 253.	1.6	44
62	Market access of cancer drugs in European countries: improving resource allocation. Targeted Oncology, 2014, 9, 95-110.	1.7	33
63	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. Frontiers in Pharmacology, 0, 13, .	1.6	2